Table 2.
Combination strategies with PLK1 inhibitors: in vitro data.
| PLK1 inhibitor | Agent | Disease | Ref |
|---|---|---|---|
| volasertib/BI6727 | cisplatin | gastric cancer | (162) |
| doxorubicine | triple negative breast cancer | (163) | |
| cyclophosphamide | triple negative breast cancer | (163) | |
| fadusil (ROCK inhibitor) | lung cancer | (164) | |
| olaparib | castration-resistant prostate cancer | (165) | |
| eribulin | rabdomyosarcoma | (166) | |
| cisplatin | cervical cancer | (167) | |
| paclitaxel | ovarian cancer | (168) | |
| JTP-74017 (MEK inhibitor) | NRAS mutant melanoma | (169) | |
| MK0752 (NOTCH inhibitor) | melanoma | (170) | |
| erlotinib | NSCLC | (171) | |
| P22077 (USP inhibitor) | lung cancer | (172) | |
| onvansertib/NMS-1286937 | paclitaxel | triple negative breast cancer | (173) |
| docetaxel | triple negative breast cancer | (173) | |
| GSK461364 | paclitaxel | triple negative breast cancer | (173) |
| docetaxel | triple negative breast cancer | (173) | |
| BRD4 inhibitor | castration-resistant prostate cancer | (174) |